You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 28, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Researchers identified GIV (CCDC88A) in macrophages as key to PD1 blockade response. GIV loss promotes hyperprogressive disease (HPD) by disrupting PD1 receptor removal, highlighting a new target for cancer immunotherapy.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: